AN2 Therapeutics vs NanoViricides
ANTX and NNVC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANTX and NNVC compare
AN2 Therapeutics is the larger company, worth 5.5 times as much as NanoViricides ($172M against $31.4M).
AN2 Therapeutics scores higher on the StockData Score (7 against 5 for NanoViricides), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANTX | NNVC |
|---|---|---|
| Size and price | ||
| Market cap | $172M | $31.4M |
| Share price | $4.55 | $1.23 |
| Change, 1 year | 286% | −18.0% |
| Change, 5 years | – | −73.2% |
| Beta (5Y) | 0.92 | 0.77 |
| Employees | 21 | 7 |
| StockData Score | ||
| Total score | 7 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 2.3× (better) | 3.6× |
| FCF yield | – | −24.8% |
| Profitability | ||
| Return on equity | −51.3% (better) | −101% |
| Return on invested capital | −618% | −111% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 10.48 (better) | 2.66 |
| Altman Z-score | 10.78 (better) | −9.11 |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −6.1% |
| Shareholder yield | 0.00% (better) | −6.1% |
| Ownership | ||
| Held by institutions | 65.1% | 9.3% |
| Held by insiders | 20.2% | 0.00% |
| Insider net buying, 12 months | −$395K | – |
| Short interest, % of float | 8.1% | 3.2% |
Go deeper
- ANTX stock overview
- ANTX income statement
- ANTX valuation and score
- NNVC stock overview
- NNVC income statement
- NNVC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.